{
    "clinical_study": {
        "@rank": "9766", 
        "arm_group": [
            {
                "arm_group_label": "Kovacaine Mist High Dose", 
                "arm_group_type": "Experimental", 
                "description": "400uL of Kovacaine Mist, as 2 sprays of 200uL."
            }, 
            {
                "arm_group_label": "Kovacaine Mist Mid Dose", 
                "arm_group_type": "Experimental", 
                "description": "200uL of Kovacaine Mist, as 2 sprays of 100uL."
            }, 
            {
                "arm_group_label": "Kovacaine Mist Low Dose", 
                "arm_group_type": "Experimental", 
                "description": "120uL of Kovacaine Mist, as 2 sprays of 60uL."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the efficacy and safety of intranasally administered\n      Kovacaine Mist for anesthetizing maxillary teeth in pediatric subjects."
        }, 
        "brief_title": "Dose-Ranging Study of Intranasal Kovacaine Mist in Pediatric Subjects", 
        "completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "condition": "Anesthesia", 
        "detailed_description": {
            "textblock": "This is a single-center, open-label, randomized, parallel-groups, dose-ranging study to\n      assess the efficacy and safety of intranasally administered Kovacaine Mist for anesthetizing\n      maxillary teeth in pediatric subjects.\n\n      The study will employ an open-label design to determine the lowest effective doses (LEDs),\n      and assess the safety and efficacy of Kovacaine Mist administered intranasally for inducing\n      pulpal anesthesia of maxillary primary teeth numbers A to J and maxillary permanent teeth\n      numbers 4 to 13 (maxillary right second premolar to maxillary left second premolar)\n      sufficient to allow completion of the Study Dental Procedure, and will be carried out in\n      healthy children of either sex between the ages of 3 and 17 years, inclusive."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female 3-17 years of age inclusive.\n\n          -  Need for an operative restorative dental procedure on a single vital maxillary\n             primary tooth (#A to J) or permanent tooth (#4 to13), other than a maxillary\n             permanent first, second or third molar, requiring local anesthesia with an expected\n             treatment duration not exceeding 60 minutes.\n\n          -  Normal lip, nose, eyelid, and cheek sensation.\n\n          -  Accompanied and/or represented by a parent or guardian able to comprehend and sign\n             the informed consent document.\n\n          -  If age 8 and above, able to understand and provide informed assent.\n\n          -  Patient or parent/guardian able to communicate with the investigator and comply with\n             the requirements of the protocol.\n\n          -  Patency of the naris ipsilateral to the tooth undergoing the Study Dental Procedure.\n\n          -  Minimum weight: Subjects in Cohorts A and B (age 6 and above) must weigh at least\n             20kg (44 lb.). Subjects in Cohort C (age 3 and above) must weigh at least 10kg (22\n             lb.).\n\n        Exclusion Criteria:\n\n          -  Dental care requiring a local anesthetic within the 24 hours prior to anticipated\n             study participation.\n\n          -  History of allergy to or intolerance of tetracaine, benzyl alcohol, other ester local\n             anesthetics, or para-aminobenzoic acid (as found in PABA-containing sunscreen).\n\n          -  History of allergy or hypersensitivity to lidocaine, oxymetazoline, epinephrine, or\n             sulfite preservatives.\n\n          -  Use of a monoamine oxidase inhibitor within the 3 weeks preceding study entry.\n\n          -  Nursing, pregnant, suspected of being pregnant, or trying to become pregnant.\n             (Females of child-bearing potential will be required to take a urine pregnancy test\n             on the day of, but prior to, study drug administration to rule out pregnancy.)\n\n          -  Inadequately controlled thyroid disease of any type.\n\n          -  Use of any investigational drug (including Kovacaine Mist) and/or participation in\n             any clinical trial within 30 days of study participation.\n\n          -  Frequent nose bleeds (\u2265 5 per month).\n\n          -  Anticipated need for use of oxymetazoline or phenylephrine nasal spray, nasal\n             irrigation, or other nasal or oral decongestant on the day of the study procedure.\n\n          -  History of congenital or idiopathic methemoglobinemia.\n\n          -  Clinically relevant history of sinus/nasal surgery, recent epistaxis, nasal\n             congestion or sinus infections, or use of a \"sinus medication\" within the 48 hours\n             prior to anticipated study participation.\n\n          -  History of alcoholism and/or drug abuse.\n\n          -  Pulpal pathology in the index tooth.\n\n          -  Anticipated need for use of nitrous oxide before or during the Study Dental\n             Procedure.\n\n          -  Any chronic or currently uncontrolled psychogenic, neurological, endocrine,\n             pulmonary, cardiovascular, renal, gastrointestinal or hepatic disease or condition\n             with manifestations that might confound interpretation of study results or make\n             receipt of study medication a source of risk for adverse outcome.\n\n          -  Fever defined as body temperature \u2265100\u00b0 (37\u00b0C) on the day of and prior to study drug\n             administration."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "17 Years", 
            "minimum_age": "3 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01701505", 
            "org_study_id": "SR 2-03"
        }, 
        "intervention": [
            {
                "arm_group_label": "Kovacaine Mist High Dose", 
                "description": "2 unilateral intranasal sprays of 200uL each.", 
                "intervention_name": "400uL of Kovacaine Mist", 
                "intervention_type": "Drug", 
                "other_name": "Tetracaine HCl 3% and Oxymetazoline HCl 0.05%"
            }, 
            {
                "arm_group_label": "Kovacaine Mist Mid Dose", 
                "description": "2 unilateral intranasal sprays of 100uL each.", 
                "intervention_name": "200uL of Kovacaine Mist", 
                "intervention_type": "Drug", 
                "other_name": "Tetracaine HCl 3% and Oxymetazoline HCl 0.05%"
            }, 
            {
                "arm_group_label": "Kovacaine Mist Low Dose", 
                "description": "2 unilateral intranasal sprays of 60uL each.", 
                "intervention_name": "120uL of Kovacaine Mist", 
                "intervention_type": "Drug", 
                "other_name": "Tetracaine HCl 3% and Oxymetazoline HCl 0.05%"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Tetracaine", 
                "Oxymetazoline", 
                "Phenylephrine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "operative", 
            "dental procedure"
        ], 
        "lastchanged_date": "December 6, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Fort Collins", 
                    "country": "United States", 
                    "state": "Colorado", 
                    "zip": "80525"
                }, 
                "name": "Big Grins"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 2, Single-Center, Open-Label, Randomized, Parallel-Groups, Dose-Ranging Study to Assess the Efficacy and Safety of Intranasally Administered Kovacaine Mist for Anesthetizing Maxillary Teeth in Pediatric Subjects", 
        "overall_official": {
            "affiliation": "University of Pittsburgh", 
            "last_name": "Paul A. Moore, DMD/PhD/MPH", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Completion of the Study Dental Procedure without need for rescue by injection of local anesthetic(yes/no)", 
            "safety_issue": "No", 
            "time_frame": "at 14 minutes with a 3 minute window"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01701505"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Incidence of adverse events (AEs) by age and dose.", 
                "safety_issue": "Yes", 
                "time_frame": "from baseline to 24 hours following drug administration"
            }, 
            {
                "description": "The principal investigator will perform a visual inspection to note any abnormalities", 
                "measure": "Naris examination (NE) to assess reactions to the study drug.", 
                "safety_issue": "Yes", 
                "time_frame": "At 120 Minutes"
            }, 
            {
                "measure": "Systolic Blood Pressure", 
                "safety_issue": "Yes", 
                "time_frame": "At 12 minutes and 120 minutes"
            }, 
            {
                "measure": "Diastolic Blood Pressure", 
                "safety_issue": "Yes", 
                "time_frame": "At 12 minutes and 120 minutes"
            }, 
            {
                "measure": "Heart Rate", 
                "safety_issue": "Yes", 
                "time_frame": "At 12 minutes and 120 minutes"
            }, 
            {
                "measure": "Oxygen Saturation", 
                "safety_issue": "Yes", 
                "time_frame": "At 12 minutes and 120 minutes"
            }
        ], 
        "source": "St. Renatus, LLC", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Triligent International", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Tegra Analytics", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "St. Renatus, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}